Seattle Genetics (SGEN) PT Raised to $135 at Needham & Company, Following Approval of Bladder Cancer Drug
Tweet Send to a Friend
Needham & Company analyst Chad Messer raised the price target on Seattle Genetics (NASDAQ: SGEN) to $135.00 (from $130.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
